LAG-3 Antagonist - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “LAG-3 Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in LAG-3 Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
LAG-3 Antagonist: Overview
LAG-3 is Lymphocyte Activation Gene-3 (LAG-3 or CD223) is a cell surface molecule expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. It is involved in the regulation of the immune system. LAG3 was discovered by Triebel and colleagues in 1990 as a novel 498-amino acid type I transmembrane protein. Under physiological conditions, LAG3 is an activation marker for CD4+ and CD8+ T cells. LAG-3 plays an important role in modulating T cell expansion and function, and blockade of LAG-3 with monoclonal antibodies can augment T cell function in multiple models. Lymphocyte Activation Gene-3 is a potential cancer immunotherapeutic target due to its negative regulatory role on T cells and its capacity, in combination with PD1, to mediate a state of exhaustion. Several LAG3 modulating immunotherapeutics are currently in various stages of clinical and pre-clinical development.
Report Highlights
This segment of the LAG-3 Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
LAG-3 Antagonist Emerging Drugs
Further product details are provided in the report……..
LAG-3 Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different LAG-3 Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
LAG-3 Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses LAG-3 Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging LAG-3 Antagonist drugs.
LAG-3 Antagonist Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “LAG-3 Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in LAG-3 Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
LAG-3 Antagonist: Overview
LAG-3 is Lymphocyte Activation Gene-3 (LAG-3 or CD223) is a cell surface molecule expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. It is involved in the regulation of the immune system. LAG3 was discovered by Triebel and colleagues in 1990 as a novel 498-amino acid type I transmembrane protein. Under physiological conditions, LAG3 is an activation marker for CD4+ and CD8+ T cells. LAG-3 plays an important role in modulating T cell expansion and function, and blockade of LAG-3 with monoclonal antibodies can augment T cell function in multiple models. Lymphocyte Activation Gene-3 is a potential cancer immunotherapeutic target due to its negative regulatory role on T cells and its capacity, in combination with PD1, to mediate a state of exhaustion. Several LAG3 modulating immunotherapeutics are currently in various stages of clinical and pre-clinical development.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence LAG-3 Antagonist R&D. The therapies under development are focused on novel approaches for LAG-3 Antagonist.
- On 5th May 2020 Crescendo Biologics and Cancer Research announced a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody® immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need. Under the terms of the agreement, Cancer Research UK’s Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213, in patients with solid tumors.
This segment of the LAG-3 Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
LAG-3 Antagonist Emerging Drugs
- Tebotelimab: MacroGenics
- LAG525: Novartis
Further product details are provided in the report……..
LAG-3 Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different LAG-3 Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on LAG-3 Antagonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
LAG-3 Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses LAG-3 Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging LAG-3 Antagonist drugs.
LAG-3 Antagonist Report Insights
- LAG-3 Antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing LAG-3 Antagonist drugs?
- How many LAG-3 Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for LAG-3 Antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the LAG-3 Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for LAG-3 Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- MacroGenics
- Novartis
- Merck Sharp & Dohme
- Crescendo Biologics
- F-star Therapeutics
- MICROBIO Group
- Bristol-Myers Squibb
- Ono Pharmaceuticals
- Symphogen
- Avacta
- Abeome Corporation
- Tebotelimab
- LAG525
- Favezelimab
- CB213
- FS-118
- SNA-03
- Relatlimab
- Sym022
- AVA-0017
- LAG3 antagonist
Introduction
Executive Summary
LAG-3 Antagonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
LAG-3 Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
LAG-3 Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
LAG-3 Antagonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tebotelimab: MacroGenics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
FS-118: F-star Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CB213: Crescendo Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
LAG-3 Antagonist Key Companies
LAG-3 Antagonist Key Products
LAG-3 Antagonist- Unmet Needs
LAG-3 Antagonist- Market Drivers and Barriers
LAG-3 Antagonist- Future Perspectives and Conclusion
LAG-3 Antagonist Analyst Views
LAG-3 Antagonist Key Companies
Appendix
Executive Summary
LAG-3 Antagonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
LAG-3 Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
LAG-3 Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
LAG-3 Antagonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tebotelimab: MacroGenics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
FS-118: F-star Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CB213: Crescendo Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
LAG-3 Antagonist Key Companies
LAG-3 Antagonist Key Products
LAG-3 Antagonist- Unmet Needs
LAG-3 Antagonist- Market Drivers and Barriers
LAG-3 Antagonist- Future Perspectives and Conclusion
LAG-3 Antagonist Analyst Views
LAG-3 Antagonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for LAG-3 Antagonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for LAG-3 Antagonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for LAG-3 Antagonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for LAG-3 Antagonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
